WEBULL
News
RVNC
3.650
0.00%
0.000
Evolus posts quarterly profit on strong sales of cosmetic injection
Reuters · 03/04 21:05
*News On Revance Therapeutics Inc. (RVNC) Now Under CRWN.XX
Dow Jones · 02/06 22:08
Revance Therapeutics Finalizes Merger with Crown Laboratories
TipRanks · 02/06 14:35
Revance’s acquisition by Crown Laboratories completed
TipRanks · 02/06 13:46
Press Release: Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics
Dow Jones · 02/06 13:39
*Crown Laboratories Announces Completion Of Acquisition Of Revance Therapeutics RVNC
Dow Jones · 02/06 13:39
Press Release: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Dow Jones · 02/05 13:00
*Crown Laboratories, Revance Therapeutics Announce Expiration of Tender Offer
Dow Jones · 02/05 13:00
Weekly Report: what happened at RVNC last week (0127-0131)?
Weekly Report · 02/03 10:51
Revance’s board urges stockholders to vote in favor of Crown’s acquisition offer
TipRanks · 01/31 12:41
REVANCE STOCKHOLDERS URGED TO TENDER THEIR SHARES IN SUPPORT OF CROWN TRANSACTION BY THE FEBRUARY 4TH DEADLINE
Reuters · 01/31 12:30
Press Release: Revance Stockholders Urged to -2-
Dow Jones · 01/31 12:30
Press Release: Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline
Dow Jones · 01/31 12:30
Hold Rating Maintained Amidst Revance Therapeutics Acquisition Uncertainty
TipRanks · 01/31 07:57
Teoxane Ends Revance Pursuit After Revised Crown Deal
Dow Jones · 01/30 16:25
Teoxane withdraws takeover offer for Revance Therapeutics
Seeking Alpha · 01/30 14:16
Weekly Report: what happened at RVNC last week (0120-0124)?
Weekly Report · 01/27 10:53
Key deals this week: Paramount Global, Toronto-Dominion Bank, Beacon Roofing Supply and more
Seeking Alpha · 01/25 19:35
REVANCE THERAPEUTICS INC <RVNC.O>: MIZUHO RAISES TARGET PRICE TO $3.65 FROM $3.10
Reuters · 01/22 11:43
Mizuho Securities Remains a Hold on Revance Therapeutics (RVNC)
TipRanks · 01/22 04:35
More
Webull provides a variety of real-time RVNC stock news. You can receive the latest news about Revance Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RVNC
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers.